


The fund’s investment objective is to achieve capital growth. The fund will invest in healthcare, medical services and related products and companies on a world wide basis. Investment will be in directly held transferable securities. The fund may also invest in collective investment schemes, warrants and money market instruments.
| Name | % Net Assets |
|---|---|
| Pfizer | 5.6% |
| Johnson & Johnson | 5.6% |
| Merck & Co | 5.1% |
| Roche Holding | 4.6% |
| Abbott Laboratories | 3.9% |
| GlaxoSmithKline | 3.9% |
| Novartis | 3.7% |
| UnitedHealth Group | 3.4% |
| Sanofi | 2.8% |
| Gilead Sciences | 2.7% |
| Key | % Net Assets |
|---|---|
| 5.6% | |
| 5.6% | |
| 5.1% | |
| 4.6% | |
| 79.1% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 259.10p |
| Currency | GBP |
| Change | 0.30p |
| % | 0.12% |
| YTD change | -22.60p |
| YTD % | -8.02% |
| Fund Inception | 22/05/2000 |
|---|---|
| Fund Manager | John Bowler |
| TER | 1.68 (15-Feb-2012) |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | n/a |
| Savings | £50 |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | -0.04 |
You are here: research